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Abstract
A series of 1-(acyloxyalkyl)imidazoles (AAI) were synthesized by nucleophilic substitution of chloroalkyl esters of fatty acids with
imidazole. The former was prepared from fatty acid chloride and an aldehyde. When incorporated into liposomes, these lipids show an
apparent pKa value ranging from 5.12 for 1-(palmitoyloxymethyl)imidazole (PMI) to 5.29 for 1-[(a-myristoyloxy)ethyl]imidazole (a-MEI) as
determined by a fluorescence assay. When the imidazole moiety was protonated, the lipids were surface-active, as demonstrated by hemolytic
activity towards red blood cells. As expected, AAI were hydrolyzed in serum as well as in cell homogenate. They were significantly less toxic
than biochemically stable N-dodecylimidazole (NDI) towards Chinese hamster ovary (CHO) and RAW 264.7 (RAW) cells as determined by
MTT assay. When fed to RAW cells, fluorescein-labeled oligonucleotides encapsulated in liposomes containing 20 mol% 1-
(stearoyloxymethyl)imidazole (SMI) resulted in punctate as well as partially diffuse fluorescence. In a functional assay involving down-
regulation of luciferase in CV-1 cells, neutral liposomes containing imidazole lipids showed suboptimal delivery of antisense phosphorothioate
oligomers. Taken together, the results suggest that AAI are of potential use in developing nontoxic, pH-sensitive liposomes. However, these
liposomal formulations need to be optimized to achieve higher concentrations of pH-sensitive detergents within the endosome to facilitate
efficient cytosolic release of liposome-entrapped contents.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Membrane-impermeable macromolecules enter the
eukaryotic cell primarily via endocytosis [1]. Acidification
associated with endosome maturation has been exploited in
the design of pH-sensitive drug carriers for cytosolic deliv-
ery of therapeutic agents [2,3 and references therein]. For
instance, liposomal formulations containing dioleoyl phos-
phatidylethanolamine (DOPE), oleic acid, cholesteryl hemi-
succinate or imidazole-based amphiphiles have shown
efficient cellular delivery of encapsulated macromolecules
[4–6]. While net surface charge in such formulations can
facilitate liposome–cell interactions and enhance cellular
uptake [7,8], it tends to promote nonspecific interactions
with serum proteins causing rapid clearance from the
circulation [9,10]. Our research objective has been to
develop neutral liposomal formulations, which can be
triggered by acidic endosomal pH to release entrapped
contents to cytosol.
An imidazole (pKa = 6.9) or morpholine (pKa = 8.4) deriv-
ative containing a long alkyl chain, commonly referred to as
lysosomotropic detergents [11], becomes surface-active
when the nitrogen is protonated in the endosome. For
instance, cytotoxicity of N-dodecylimidazole (NDI) was
originally attributed to the leakage of lysosomal enzymes
into the cytosol [12]. Although the above interpretation was
disputed in subsequent studies, a consensus is that the
persistent cytotoxicity clearly originates from two sources:
surface activity and biochemical stability of the lysosomo-
tropic detergent [13–15].
In an attempt to reduce this cytotoxicity, while main-
taining the surface activity, we have developed a series of
biodegradable and thus ‘soft’ lysosomotropic 1-(acyloxyal-
kyl)imidazole (AAI) detergents (Table 1). A similar bio-
degradable, pH-sensitive surfactant, dodecyl-2-(1V-imida-
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zolyl) propionate (DIP), has been reported in the literature
[16]. While DIP is expected to degrade into imidazolyl
propionic acid and dodecyl alcohol, AAI are hydrolyzed
enzymatically to fatty acid and unstable hydroxymethyl
imidazole. The latter spontaneously releases an aldehyde
and an imidazole. In short, AAI were expected to maintain
their lysosomotropic detergency and biochemical lability.
In addition, these fatty acid derivatives should spontane-
ously insert themselves into liposomal bilayers at a wide
range of concentrations, where they would predominantly
exist as unprotonated species at neutral pH. As phagocy-
tosis by the target cell proceeds, the liposomes would
encounter an acidic endosomal environment [17]. From
this point on, a cascade of events should occur as shown in
Fig. 1.
As endosomal pH drops, the imidazole moiety will be
protonated with a diffuse positive charge between the N1
and N3 positions. The increase in hydration associated with
protonation is expected to induce membrane defects and
significant leakage of the entrapped macromolecules. In
addition, upon protonation, AAI would become surface-
active, creating transient defects or pores in the endosomal
membrane that would eventually allow mass transfer into
the cytosol [18,19]. The structure–activity relationship in
this context constitutes the crux of the present in vitro
study.
2. Materials and methods
2.1. Lipids and chemicals
N-Tetradecylimidazole (NTI) and the following AAI
were provided by Megabios Corp. (Burlingame, CA): 1-
(palmitoyloxymethyl)imidazole (PMI), 1-(stearoyloxyme-
thyl)imidazole (SMI), 1-(oleoyloxymethyl)imidazole
(OMI), and 1-(linoleoyloxymethyl)imidazole (LMI). Egg
phosphatidylcholine (EPC), dipalmitoyl phosphatidylcho-
line (DPPC), and DOPE were obtained from Avanti Polar
Lipids, Inc. (Alabaster, AL). Myristoyl chloride, paralde-
hyde, (3-[4,5 -yl]-2,5-diphenyltetrazolium bromide (MTT),
potassium 2-( p-toluidino) naphthalene-6-sulfonate (TNS),
nigericin, calcein, and cholesterol were purchased from
Sigma Chemical Co. (St. Louis, MO). Culture medium,
fetal bovine serum (FBS), antibiotics, and supplements were
obtained from Gibco BRL (Grand Island, NY). All other
Table 1
Structures and pKa values of AAI and other weak base lipids
a
The pKa values of NDI and NDM were obtained from Ref. [14].
b
The pKa value of DIP was obtained from Ref. [16].
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chemicals or reagents were obtained from Aldrich Chemical
(Milwaukee, WI). Unless mentioned otherwise, all materials
were used as received without any further purification.
2.2. Synthesis
1-(Myristoyloxymethyl)imidazole (MMI) and 1-[(a-myr-
istoyloxy)ethyl]imidazole (a-MEI) were prepared according
to Bodor [20]. Typical synthetic procedure is illustrated for
MMI: 1 ml (3.57 mmol) of myristoyl chloride and 113 mg
(3.57 mmol) of paraformaldehyde were heat-sealed in an
ampule and maintained at 95 jC for 3 days. The reaction
mixture was diluted in hexane then chromatographed on
silica gel eluting with hexane/EtOAc (98:2, v/v), then on
FlorisilR, eluting with hexane followed by hexane/EtOAc
(98:2, v/v). Approximately 945mg of chloromethyl myristate
was obtained and the yield of this reaction was f 31%. The
purity of the product was examined by silica gel TLC which
showed only one spot: Rf = 0.50 [hexane/EtOAc (95:5, v/v)].
1H NMR (CDCl3): d 5.7 (s, 2H), 2.4 (t, 2H), 1.6–1.7 (m, 2H),
1.3 (br s, 20H), 0.9 (t, 3H). To a solution of 915 mg (3.30
mmol) of chloromethyl myristate in 20ml of CH3CN, 270mg
(3.97 mmol) of imidazole was added and refluxed at 82 jC
for 12 h. The solvent was removed and methylene chloride
half saturated with a 28% ammonium hydroxide aqueous
solution was added to neutralize the HCl generated from the
reaction. The clear filtrate of the reaction mixture in CH2Cl2
was concentrated and chromatographed on silica gel eluting
with CH2Cl2/EtOAc/MeOH (90:8:2, v/v).
Approximately 625 mg of the free base of MMI was
obtained and was subsequently converted to HCl salt. The
free base (300 mg) dissolved in 15 ml of anhydrous diethyl
ether was bubbled with anhydrous HCl gas. The HCl salt of
MMI precipitated out from the ether immediately was col-
lected by filtration through a medium-porosity sintered glass.
Approximately 260 mg of MMIHCl was obtained after
drying the precipitate under vacuum overnight and the yield
of this reaction was about 47.6%. The purity of the product
was examined by silica gel TLC, which showed only one
spot: Rf = 0.31 [CH2Cl2/EtOAc/MeOH (80:18:2, v/v)], m.p.
112–114 jC. 1HNMR (CDCl3): d 9.8 (s, 1H), 7.4 (d, 2H), 6.3
(s, 2H), 2.4 (t, 3H), 1.6 (br m, 2H), 1.2–1.3 (br s, 20H), 0.9 (t,
3H). FAB-MS: m/z 309.2 (M +H+). Anal. calculated for
C18H33N2O2Cl: C, 62.68, H, 9.64, N, 8.12, Cl, 10.28. Found:
C, 62.55, H, 9.70, N, 8.10, Cl, 10.28. In all instances, the
NMR spectra were recorded on a Bruker AC-300 spectrom-
eter; FAB-MS spectra were obtained from a VG-70-250 SEQ
mass spectrometer; and elemental analysis performed by
Atlantic Microlab (Norcross, GA).
For the HCl salt of a-MEI HCl, Rf = 0.35 [CH2Cl2/EtOAc/
MeOH (80:18:2, v/v)], m.p. 74–76 jC. 1H NMR (CDCl3): d
9.4 (s, 1H), 7.4 (d, 2H), 6.9 (q, 2H), 2.4 (br m, 3H), 1.9 (d,
2H), 1.6 (brm, 2H), 1.25 (br s, 20H), 0.9 (t, 3H). FAB-MS:m/z
323.2 (M+H+). Anal. calculated for C19H35N2O2Cl: C,
63.58, H, 9.83, N, 7.80, Cl, 9.88. Found: C, 63.37, H, 9.80,
N, 7.83, Cl, 9.94.
2.3. Preparation of liposomes
For pKa measurement and cytotoxicity study of AAI,
blank liposomes were prepared by freeze-thaw and extrusion
method [21]. Briefly, EPC, cholesterol, and AAI (45:45:10 in
molar ratio), dissolved in chloroform/ethanol mixture, were
evaporated in vacuo to form lipid films. After drying over-
night under high vacuum, dry lipid films were hydrated with
phosphate buffered saline (PBS) by vortexing. The resulting
multilamellar vesicles were freeze-thawed in a dry ice/
acetone bath and lukewarm water bath for six cycles. The
liposomes were extruded through two stacked 0.1 AM
polycarbonate membranes (Poretics, Livermore, CA) by
nitrogen at room temperature for 10 times with an extruder
(Lipex Biomembranes, Vancouver, Canada).
Fig. 1. Rationale and proposed mechanism of cytosolic delivery mediated by AAI. Upon incorporation into liposomes, AAI are endocytosed into target cells. In
the acidic endosomal milieu, the imidazole lipids acquire surface activity, which results in sequential permeabilization of both the liposomes and endosomes,
thus allowing entrapped drug molecules to escape to the cytosol of cells. To reduce cytotoxicity, AAI are designed to be biodegradable. Following enzymatic
hydrolysis of the ester bond, the resulting hydroxymethyl imidazoles are expected to rapidly breakdown into imidazole and the corresponding aldehyde.
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Liposomes containing antisense phosphorothioate oligo-
nucleotides (S-ODN) or fluorescein conjugated phosphor-
othioate oligonucleotides (F-ODN) were prepared by
freeze-thaw and extrusion along with the minimum volume
entrapment method for high entrapment of oligonucleotides.
Briefly, dry lipid films of AAI and other natural occurring
lipids were hydrated in 40–60 Al of distilled water con-
taining 30–90 nmol of F-ODN by alternatively vortexing
and storing at 4 jC overnight. The lipid suspensions were
then diluted in 1 ml of PBS and freeze-thawed. The
resulting vesicles were extruded through two stacked 0.1-
Am polycarbonate membranes 12 times by N2 head pres-
sure. Unentrapped F-ODN was removed by spin column gel
permeation chromatography on Sepharose CL-6B in a 20-
ml syringe and eluted with PBS [22]. In all cases, less than
3 ml of the liposome preparation was applied to the gel bed.
The column was spun at 40 g for 5 min at 4 jC to
facilitate elution of the oligonucleotide-containing lipo-
somes. Free F-ODN retained by Sepharose beads was
recovered by washing the column.
The S-ODN concentrations in liposome preparations were
determined by capillary electrophoresis. Briefly, a 200-Al
aliquot of the liposome fraction was dissolved in 400 Al of
isopropanol and all the solvents were removed subsequently.
The residue was reconstituted in 400 Al of deionized water
and the suspension was centrifuged at 16,000 g for 20 min.
The clear supernatant was withdrawn and S-ODN analyzed
in a Beckman P/ACE System 2000 (Fullerton, CA) equipped
with a capillary (50 cm 75 Am cartridge). The capillary
was then eluted with 100 mM sodium borate at pH 8.35,
driven by a voltage of 30 kVat 23 jC. Appearance of S-ODN
was monitored by a UV detector at 214 nm. Entrapment of S-
ODN was also estimated by subtracting the amount of
unencapsulated S-ODN obtained based on the UV absorb-
ance of liposome-free fractions at 260 nm. The F-ODN
concentration of the liposome preparations was determined
by a fluorescence assay on a Perkin Elmer LS-50B spectro-
fluorometer (Norwalk, CT) with kex = 485 nm and kem = 516
nm. Entrapped F-ODN was released by adding 200 Al of 1%
triton X-100 solution to 100 Al of liposome preparation, and
then diluted to 2 ml in deionized water. Size distribution of
the liposomes was determined by photon correlation spec-
troscopy using a NICOMP 370 submicron particle sizer
(Particle Sizing Systems, Santa Barbara, CA). The osmolal-
ity of liposome preparations was determined by means of
freezing-point depression measurement on a Fiske ONE-
TEN Osmometer (Fiske Associates, Norwood, MA).
2.4. Determination of pKa of AAI in liposomes
Blank unilamellar vesicles containing AAI, EPC, and
cholesterol were diluted to 60 AM of total lipid in 150 mM
NaCl, 5 mM HEPES, 5 mM ammonium acetate, 20AMTNS,
and 0.1 AM nigericin at pH ranging from 2 to 10. The surface
charge of liposomes at each pH was monitored by determin-
ing the TNS fluorescence in a Perkin Elmer LS-50B spec-
trofluorometer using kex = 332 nm and kem = 440 nm [23].
Data were subjected to least square analysis (MINSQ pro-
gram) using the following equation to obtain values of pKa,
where A and B are constants.
Fluorescence ¼ Aþ B Ka
Ka þ ½Hþ
2.5. pH-dependent surface activity of AAI
Human erythrocytes were suspended in 50 ml of buffers
at 2.5 107 cells/ml with a pH range of 5.0 to 7.5 at 37 jC
under constant hydrodynamic conditions. A stock solution of
MMI in ethanol was added to the suspended erythrocytes to a
final concentration 0.05 mM with 2% of ethanol. At each
time point, 1 ml of the suspension was withdrawn and
centrifuged at 2000 g for 1 min at room temperature.
The absorbance of the clear supernatant at 533 nm was
measured in a Shimadzu UV/Vis spectrophotometer (Kyoto,
Japan). Complete hemolysis was determined by adding
Triton X-100 to the suspended erythrocytes in the presence
of 2% ethanol so that the final concentration was 0.01%.
Negative controls were obtained by suspending the eryth-
rocytes in buffers of pH ranging from 5.0 to 7.5 in the
presence of 2% ethanol.
2.6. Cell culture and oligonucleotides
Chinese hamster ovary (CHO) and RAW 264.7 (RAW)
cell lines were obtained from American Type Culture Col-
lection (Rockville, MD). CV-1 cells expressing luciferase
were a generous gift from Dr. C. Leamon formerly at Glaxo
(Research Triangle Park, NC). All cells were maintained as
plated at 37 jC in a humidified atmosphere of 5% CO2, a-
MEM supplemented with L-glutamine, antibiotics, and 10%
heat-inactivated FBS for CHO cells; RAW cells in DMEM-H
medium supplemented with L-glutamine, antibiotics, and
10% heat-inactivated FBS; and CV-1 cells in MEM supple-
mented with essential amino acids, sodium pyruvate, anti-
biotics, and 10% heat-inactivated FBS.
Antisense oligomers (S-ODN and 3V-labeled F-ODN)
were prepared by the Nucleic Acid Core Facility in the
Lineberger Cancer Research Center of UNC (Chapel Hill,
NC). The oligonucleotide (5V-TGGCGTCTTCCATTT-3V)
complementary to the initiation codon region of the lucifer-
ase mRNA of the CV-1 cells has been known to inhibit the
translation of luciferase [24].
2.7. Biodegradability of AAI
Stability of AAI was determined at 37 jC in human serum
(Sigma) and in CHO cell homogenate. The latter was
prepared by homogenizing CHO cells in exponentially
growing phase at 3 107 cell/ml in PBS on ice with a tissue
homogenizer (Thomas Scientific, Swedesboro, NJ). Cell
number was determined using a hemocytometer. The result-
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ing cell homogenate was kept frozen at  20 jC until further
use.
Stock solutions of AAI prepared in ethanol were added to
human serum or CHO cell homogenate at 37 jC in such a
way that the initial concentration of AAI was 0.1 mM and
ethanol concentration was 2% in all the samples. The
samples were then incubated in a water bath maintained at
37 jC. At each time point, a 300-Al aliquot of the sample was
withdrawn and mixed with 300 Al of cold acetonitrile by
vortexing, then centrifuged at 16,000 g for 7 min. The
concentration of AAI remaining in the clear supernatant was
determined by an HPLC assay. Human serum samples of
PMI, OMI, and NTI were analyzed on a EconisilR C18
column (10 Am, 250 4.6 mm) (Alltech, Deerfield, IL)
eluting with a mobile phase of 40% isopropanol, 40%
methanol, and 20% pH 8, 0.05% (v/v) 3-amino-1-propanol
aqueous solution at a flow rate of 1.5 ml/min. Human serum
samples of other AAI and CHO cell homogenate samples
were analyzed on a EconisilR C8 column (10 Am, 250 4.6
mm) (Alltech) eluting with a mobile phase of 40% isopro-
panol, 40% methanol, and 20% 25 mM Na2PO4 aqueous
solution at pH 5, at a flow rate of 1.0 ml/min. The eluent was
monitored by a Rainin DynmaxR model UV-C detector at
220 nm and recorded by a Shimadzu Chromatopac CR601
integrator.
2.8. Cytotoxicity of AAI
The cytotoxicity of AAI to CHO and RAW cells was
evaluated by the MTT assay [25]. Briefly, AAI, either in
ethanol or in liposomes, were diluted in culture media
containing serum and incubated with cells in 96-well plates
at a cell density of 2.5 104 for LC50 and at 1.25 104 cells
for IG50 determination. In the former, the final ethanol
concentration was 1% and the total lipid concentration was
10-fold higher than that used for the latter. Cells were
incubated with AAI at 37 jC for 90 min for the determi-
nation of LC50 and 48 h for the determination of IG50. At the
end of incubation, MTT solution was added to each well, and
plates were incubated for an additional 4 h. After aspirating
the media, 0.05 N HCl in DMSO was added to dissolve the
MTT formazan produced by the cells. The absorbance at 490
nm was read on a Bio-Rad plate reader (Hercules, CA) and
used in calculating the cell viability according to the liter-
ature [25].
2.9. Intracellular distribution of F-ODN
CV-1 cells were grown on a coverslip inside the six-well
plate at a seeding concentration of 4 105 cells/well. After
24 h of incubation, cells were incubated with F-ODN alone
or liposomes containing F-ODN in culture medium with or
without 10% FBS at 37 jC. The cells were then washed in
PBS and fixed with 4% formaldehyde in PBS at 4 jC for 15
min. To preserve the specimen, cells were immersed in a 1:1
mixture of glycerol and PBS in the dark at 4 jC after
removing the fixative by aspiration. The cells were later
examined using a Zeiss Axiovert 100 TV fluorescence
microscope excited at 488 nm.
2.10. Antisense activity of S-ODN facilitated by AAI
Luciferase-expressing CV-1 cells were seeded at 2 105
cells in each well of six-well plates. After 24 h of incubation,
cells were incubated with S-ODN alone or liposomes entrap-
ping S-ODN in culture medium with or without 10% whole
FBS for 4 h at 37 jC. The liposomes were removed by
aspiration, replaced with media containing 10% heat-inacti-
vated FBS, and incubated for another 20 h. At the end of
incubation, cells were immediately processed for determin-
ing the level of luciferase expression using the Enhanced
Luciferase Assay Kit (Analytic Luminescence Laboratory,
Ann Arbor, MI) on a Monolight 2010 luminometer. Cell
viability based on total protein per well was determined by
BCA protein assay (Pierce) on a Bio-Rad model 3550
microplate recorder. Luciferase inhibition was obtained by
normalizing the relative luminescent unit (RLU) against the
total protein and compared with the negative control.
3. Results
3.1. pKa of AAI in liposomes
The pH dependence of fluorescence intensity of TNS
upon incorporation in liposomes containing AAI is shown in
Fig. 2; and the pKa of AAI and similar lipophilic weak bases
summarized in Table 1. The pKa value of NTI that we
obtained, 6.33, is in good agreement with that of NDI, 6.3
[14]. As expected, the pKa of AAI remains approximately the
same (5.16F 0.03), despite structural differences in their
fatty acid chains. The pKa of a-MEI is about 0.13 units
higher than the average pKa of AAI. However, the pKa values
of all AAI are significantly lower (1.0–1.2 unit) than that of
the plain tertiary amine NTI.
3.2. pH-dependent surface activity of AAI
AAI are practically insoluble in water even at a pH close
to their pKa, however, soluble at lower pH. Considering the
potential hydrolysis of the ester bond at low pH, only the
most stable a-MEI was subject to determination of the
critical micellar concentration at pH 2.7: 1.5 10 4 M when
measured by surface tension using a Kru¨ss digital tensiom-
eter (platinum–iridium ring) at 25 jC. The reduction in
surface tension was about 40 dyne/cm (data not shown).
As shown in Fig. 3A, hemolysis of erythrocytes by MMI
at neutral pH showed a lag time of 20 min, and 100%
hemolysis was achieved 50 min after adding MMI. At pH
6.0, the onset time decreased to 10 min, and it took only
about another 10 min to reach 100% hemolysis. Upon further
decrease of pH to 5.5, the lag time was only about 2 min and
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hemolysis was complete within 6 min. Finally, at pH 5.0 or
lower, the hemolysis occurred instantly upon adding MMI. A
comparison of the pH-titration profile of MMI with the
equivalent rate of hemolysis (reciprocal of time required to
achieve 55% of total hemolysis) with respect to changes in
pH is shown in Fig. 3B. At pH 6, one pH unit higher than the
pKa of MMI, protonation of as little as 10%MMI seems to be
sufficient to induce the observed rapid increase in the
hemolysis rate. When about 50% MMI was activated at
pH 5.0, hemolysis appears to reach the maximum rate.
3.3. In vitro stability of AAI
The control compound NTI was stable in both human
serum and CHO cell homogenate within the time frame of
the experiment. In contrast, all AAI were found to degrade in
human serum and CHO cell homogenate at 37 jC following
a first-order kinetic process up to four half-lives (raw data not
shown). The apparent first-order rate constants of decom-
position of AAI in human serum (kS) and in CHO cell
homogenate (kH) are summarized in Table 2. Interestingly,
as shown in Fig. 4, the order of stability of AAI is the same
both in human serum and CHO cell homogenate. The
stability of AAI increased with the chain length of the
saturated fatty acids, from C14 to C18. However, a dramatic
decrease in the stability was observed as the C18 fatty acid
becomes successively more unsaturated, from stearic to oleic
to linoleic acid. In addition, substitution of the a-carbon in
MMI with a methyl group made a-MEI much more stable in
serum and cell homogenate.
The intrinsic octanol–water partition coefficients (log P)
of AAI summarized in Table 2 were estimated using a
computer program ACD/ILABk (Advanced Chemistry
Development, Toronto, Ontario, Canada). When the kS was
plotted against the corresponding log P, a good linearity was
observed for the three fully saturated AAI: MMI, PMI, and
SMI (plots not shown). However, unsaturated C18 lipids
Fig. 2. pH-dependence of TNS fluorescence upon incorporation into EPC/
cholesterol liposomes containing (A) 0% (lower plot) or 10% NTI (upper
curve) and (B) a-MEI. The pKa values were obtained by nonlinear
regression analysis of the data.
Fig. 3. pH-dependent hemolysis of human erythrocytes by MMI. (A) The
time course of hemolysis by 0.05 mM MMI in erythrocyte suspensions
(2.5 107/ml) at various pH in the presence of 2% ethanol at 37 jC under
constant hydrodynamics. Complete (100%) hemolysis was obtained by
adding triton X-100 to the erythrocyte suspension. (B) The correlation
between the protonation of MMI and the effect of MMI on the hemolysis of
erythrocytes was obtained by superimposing the titration curve of MMI
(closed symbols) with the equivalent hemolysis rate caused by MMI (open
symbols; obtained by taking the reciprocal of time required to achieve 55%
of total hemolysis, dotted line).
Table 2
Apparent first-order rate constants of the degradation of AAI in serum (kS),
CHO cell homogenate (kH), their ratios and intrinsic octanol–water







a-MEI 9.3 99.3 10.7 6.61
MMI 67.4 339.8 5.0 6.27
PMI 36.2 235.0 6.5 7.33
SMI 8.1 75.3 9.2 8.39
OMI 66.5 286.4 4.3 7.87
LMI 157.9 450.1 2.9 6.44
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(OMI and LMI) deviated positively from the straight line,
while a-MEI showed negative deviation. Similar observa-
tions were also obtained when kH was plotted against the
corresponding log P. In addition, AAI were found to degrade
more rapidly in CHO cell homogenate than in serum,
supporting potential use in systemic applications in vivo.
3.4. Cytotoxicity of AAI
Biodegradable AAI were at least 10 times less cytotoxic
than the nonbiodegradable control compound, NTI, whether
they were given to cells in solution or incorporated into
liposomes (shown in Table 3). In general, the concentrations
of AAI required to kill 50% of the cells (LC50) were at least
10 times higher than that required to inhibit 50% of the cell
growth (IG50). No significant difference in the cytotoxicity
to CHO cells was observed whether imidazole lipids were
given to cells in solution or incorporated into liposomes.
However, there was significant difference in the cell growth
inhibition (IG50) by liposomal AAI in two different cell
lines. Up to threefold increase in cytotoxicity is seen for the
more phagocytic RAW cells after prolonged exposure (2
days) to AAI relative to CHO cells. An unexpected obser-
vation is that LMI and MMI incorporated into liposomes
were most toxic to RAW cells in terms of the IG50 values.
These lipids were 2–3 times more toxic than other AAI,
even though they appeared to be 4–17 times more labile in
human serum and CHO cell homogenate than a-MEI or
SMI (based on the difference in kS and kH).
3.5. Cellular uptake of antisense facilitated by AAI
Liposomes were prepared using different imidazole lipids
and other naturally occurring helper lipids to assess delivery
efficiency by means of the antisense activity of S-ODN. De-
pending on the lipid composition, each preparation showed
differences in size distribution and S-ODN entrapment. In
general, liposomes composed of AAI/EPC/DOPE entrapped
more S-ODN than those composed of AAI/EPC/cholesterol.
Further, liposomes containing saturated AAI (e.g. MMI and
SMI) entrapped more S-ODN than those containing unsatu-
rated AAI (i.e. OMI and LMI, data not shown).
The results of the functional assay were difficult to
interpret: inhibition of luciferase expression in CV-1 cells
by antisense activity of S-ODN delivered by AAI varied
from one experiment to another. However, in a series of ex-
periments, certain trends in structure–activity were observed
(Table 4).
3.6. Intracellular distribution of F-ODN
When F-ODN (0.2 AM) alone was incubated with CV-1
cells in serum-free medium at 37 jC for 4 h, they were
poorly internalized and only weak punctate fluorescence was
observed in cytosol (Fig. 5A). In the presence of 10% whole
FBS, punctate fluorescence was further attenuated (Fig. 5B).
Liposomes composed of NTI/EPC/DOPE (1:5:4) contained
0.7 AM of F-ODN in a 5 mM total lipid concentration
preparation. Upon fourfold dilution of this liposome prepa-
ration in serum-free medium, the total amount of NTI present
in the culture medium was 0.125 mM. At this concentration,
NTI appeared non-cytotoxic to CV-1 cells over the 4-h
incubation. In this case, bright, punctate fluorescence was
found in the cytosolic regions surrounding the nuclei (Fig.
Fig. 4. A comparison of apparent first-order rate constants of degradation of
AAI in human serum (kS) and CHO cell homogenate (kH, 3 107 cells/ml
of PBS) at 37 jC.
Table 3
Cytotoxicity of AAI and NTI on CHO and RAW cells by MTT assaya
Cell line CHO RAW









NTI 0.08 0.08 0.02 0.02 0.16 0.015
a-MEI >1.0 0.13 >1.0 0.12
MMI 1.5 >1.0 0.15 0.12 >1.0 0.04
PMI f 10.0 >1.0 0.12 0.12 >1.0 0.12
SMI f 10.0 >1.0 0.12 0.12 >1.0 0.12
OMI f 10.0 >1.0 0.18 0.15 >1.0 0.08
LMI 2.0 1.0 0.15 0.13 >1.0 0.04
Plainb >10.0 >10.0 >10.0 5.2
LC50 and IG50 values are expressed in total lipid concentration (mM).
a Studies with solutions to RAW cells were not performed.
b EPC/Cholesterol 1:1 liposome was used as negative control.
Table 4







SMI/EPC/cholesterol 1:5:4 10 97 21
SMI/EPC/cholesterol 1:2:2 20 86 24
SMI/EPC/cholesterol 2:2:1b 40 74 45
SMI/EPC/DOPE 1:5:4 10 87 30
SMI/EPC/DOPE 1:2:2 20 67 51
a Single determination in CV-1 cells using an antisense luciferase down-
regulation assay in CV-1 cells.
b Unstable liposomal formulation.
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5C and D). However, no fluorescence was detected inside the
nuclei or the cytosol as a diffusive pattern.
The effect of 0%, 1%, 10%, or 20% SMI in 1:1 EPC/
DOPE liposomes on the intracellular distribution of F-ODN
is shown in Fig. 6. The average F-ODN concentration of the
four liposome preparations was 1.51F 0.14 AM and the
entrapment efficiency was approximately 30% at 5 mM total
lipid concentration. Liposomal preparations were incubated
with cells at 37 jC for 4 h after being diluted four times in
serum-free medium. No cytotoxicity was observed during
the period of experiment. In the presence of 0% or 1% SMI
in liposomes, CV-1 cells showed similar punctate fluores-
cence (Fig. 6A and B) as that observed with F-ODN
entrapped in NTI-containing liposomes. However, in the
presence of 10% or 20% SMI in the liposomes, CV-1 cells
showed not only bright punctate fluorescence in perinuclear
Fig. 6. Cellular uptake of liposomal F-ODN by CV-1 cells. F-ODN (1.5 AM) was encapsulated in SMI/EPC/DOPE liposomes (5 mM total lipid) containing (A)
0%, (B) 1%, (C) 10%, (D) 20 % of SMI. The liposome preparations were diluted fourfold in serum-free medium and given to cells. After 4-h incubation at 37 jC,
cells were fixed and examined by fluorescence microscopy.
Fig. 5. Cellular uptake of F-ODN by CV-1 cells. F-ODN (0.2 AM) was fed to cells alone in serum-free medium (A) or in the presence of 10% FBS (B). F-ODN
was also encapsulated in NTI/EPC/DOPE (1:5:4) liposomes (5 mM total lipid) and given to the cells after a fourfold dilution in serum-free medium (C) or in the
presence of 10% FBS (D). After 4-h incubation at 37 jC, cells were fixed and examined by fluorescence microscopy.
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region but also a faint but significant diffuse fluorescence in
some of the cells (Fig. 6C and D).
4. Discussion
The membrane-bound pKa of AAI was not significantly
affected by structural variations in the fatty acid chain: they
were approximately the same (5.16F 0.03). The pKa of a-
MEI is about 0.13 units higher than the average pKa of AAI
mainly due to the slight electron donating effect of the
methyl group at the a position. The pKa values of all AAI
are, however, significantly lower (1.0–1.2 unit) than that of
tertiary amine NTI, due to the electron withdrawing effect of
the ester bond next to the imidazole nitrogen. Most impor-
tantly, these results demonstrate that it is feasible to obtain
cationic surfactants of desired pKa through judicious chem-
ical modifications near the polar head group. From the pKa of
the lipophilic weak bases listed in Table 1, a very broad
spectrum of pKa can be obtained by further selecting differ-
ent weak base moieties for the polar head group of the
molecule.
The pH-dependent surface activity of AAI was demon-
strated by the pH-dependent aqueous solubility, micelle
formation, and erythrocyte hemolysis. In the latter, the
presence of various lag times implies a requirement of
minimum threshold amount of MMI that must be accumu-
lated in the plasma membrane of erythrocytes for hemoglo-
bin leakage. As there were more surface-active protonated
MMI present at a lower pH, less time was required to saturate
the membrane. However, it should be noted that the neutral
species of MMI is intrinsically active in disturbing the
erythrocyte membranes, since complete hemolysis at a
neutral pH still achieved in about 50 min. When super-
imposed upon the titration curve of MMI, the equivalent
hemolysis rate–pH profile in Fig. 3B confirms the correla-
tion between the rate of hemolysis by MMI and the amount
of the surface-active protonated MMI. This observation
suggests that one can control the rate of hemolysis or, in a
more general term, membrane permeabilization, by adjusting
the pKa of the pH-sensitive detergents.
The stability study supports that incorporation of an ester
moiety in AAI results in greater biochemical lability than
their tertiary amine analog NTI. While we have not identified
specific enzymes in either serum or cell homogenate respon-
sible for hydrolysis of the ester bond, the first-order kinetics
implies that under the experiment conditions, the esterase(s)
was not saturated with the imidazole derivatives. A linear
relationship was observed between kS and log P, and also
between kH and log P (data not shown), for the three fully
saturated AAI. This observation is consistent with a notion
that in both cases it is the free, not protein-bound, AAI in
human serum or CHO cell homogenate samples that dictated
their rate of decomposition and that the intrinsic enzymatic
activities toward all AAI are approximately the same. Hence,
parameters such as aqueous solubility, protein binding, and
self-association that determine the free AAI concentration in
biological fluids are likely the key elements determining
their overall susceptibility to enzymatic hydrolysis [26–28].
The higher lability of C18 unsaturated OMI and LMI in
serum and cell homogenate suggests that other degradation
mechanisms, in addition to the hydrolysis of the ester bond,
may be responsible for their disappearance, e.g., oxidation of
the double bonds. Finally, the serum stability of a-MEI is
attributed to steric hindrance by the a-methyl group to
enzymatic attack.
The significant decrease in cytotoxicity of AAI, in com-
parison with N-alkylimidazoles, generally supports the ‘‘soft
drugs’’ concept developed by Bodor on labile quaternary
ammonium salts [20]. However, within the group of six AAI
investigated here, the apparent stability–cytotoxicity rela-
tionship is opposite to what was expected. For example, LMI
and MMI were most labile, yet they were also the most toxic
to RAW cells, but not CHO cells. One possible explanation
for such behavior is the increased uptake of neutral lip-
osomes by the former [8]. Following uptake, the hydro-
philicity of LMI and MMI in comparison with other AAI
could result in a higher availability of free lipid within RAW
cells, thus showing increased toxicity. In the case of N-
alkylimidazoles, biochemical stability rather than increased
solubility appears to dictate their activity in vitro.
Having established structure–physicochemical property
relationships, we tested if AAI can mediate cytosolic delivery
of antisense oligonucleotides. Both fluorescent microscopy
and a functional assay were employed. The intracellular
distribution of F-ODN studied by fluorescence microscopy
can possibly explain the poor overall antisense activity
observed in the functional assay. Bright punctate fluores-
cence found in the cytosolic regions (Figs. 5 and 6) must
correspond to endocytic compartments [29]. The lack of
nuclear fluorescence staining or a diffuse fluorescence in
the cytosol suggested that no S-ODN was available to
hybridize target mRNA either in the cytosol or in the nucleus.
Although the fluorescence intensity exhibited in the cells
treated with NTI/EPC/DOPE (1:5:4) liposomes entrapping
F-ODN was greatly enhanced by the presence of 10% whole
FBS, which presumably facilitated complement-mediated
phagocytosis, no detectable diffusive fluorescence was
found in nuclei or the cytosol. However, in the presence of
10% or 20% SMI-containing liposomes, CV-1 cells showed
not only a bright punctate pattern in the cytosolic regions
surrounding the nuclei but also diffuse fluorescence in some
cells (Fig. 6C and D). This observation implies that incor-
poration of higher amounts of SMI into liposomes does
facilitate partial escape of F-ODN from endosomes and enter
the cytosol. Such intracellular distribution of F-ODN seems
to be somewhat consistent with some, but not all, of the
results obtained from the antisense activity of S-ODN.
Indeed, in agreement with the above results, a trend was
observed in the functional assay. The higher the percentage
of SMI incorporated into liposomes, the greater the inhib-
ition of luciferase expression in CV-1 cells observed.
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NTI should provide more protonated species than AAI at
a given pH because of the higher pKa of NTI. However, F-
ODN entrapped in liposomes containing NTI showed only
punctate fluorescence inside the cells in contrast to cells
treated with liposomes containing SMI. With the data avail-
able at present, we cannot adequately explain why NTI
shows less membrane-permeabilizing activity than SMI.
Having a shorter alkyl chain, it is possible that NTI is of
higher CMC, thus requiring a larger amount to disrupt both
liposomal as well as endosomal membranes [30,31]. A
corollary is that morpholine- or piperazine-based lipids with
a higher pKa and low CMC might permeabilize liposomal
and endosomal bilayers more efficiently.
Based on studies related to surfactant-induced release of
liposome contents [32,33], it is postulated that for AAI to
effectively facilitate the cytosolic delivery of antisense
oligonucleotides, a large amount of AAI needs to be accu-
mulated in one single endocytic compartment to reach a
critical phospholipid to surfactant ratio. In liposomal sys-
tems, this phospholipid-to-surfactant ratio has been shown to
increase with the size of the entrapped molecules [34]. It is
conceivable that the amount of AAI needed to reach this
critical ratio for release of macromolecules might be unat-
tainably high. In addition, the dilution of surfactants in the
endosome/lysosome milieu presents another obstacle to
reach the required concentration. An ideal surfactant must
saturate the endosomal membrane at the lowest possible
concentration to facilitate cytosolic delivery. This critical
amount, which must be accumulated in a single membrane
compartment, is limited by the potency of the surfactant to
disrupt membranes, the extent of incorporation of such lipids
in liposomal bilayers and the cellular endocytic activity.
5. Conclusion
We have prepared a series of imidazole lipids to test the
hypothesis that a lysosomotropic detergent with pH-depend-
ent activity can permeabilize the endosomal membrane and
promote cytosolic delivery of macromolecules. Acyloxyal-
kylimidazoles, each with an approximate pKa of 5.2, dis-
played pH-dependent surface activity in hemolysis experi-
ments. In addition, the imidazole lipids were degradable in
serum and cell homogenate and displayed reduced cytotox-
icity in comparison with other lipids such as NTI. However,
no supportive evidence for the cytosolic delivery of lip-
osome-entrapped antisense phosphorothioate oligos was
observed in either the functional assay or fluorescence micro-
scopy studies. Based on previous studies of surfactant-
induced release of liposomal contents, we postulate that a
large amount of imidazole lipids must be accumulated in a
single endocytic compartment for effective cytosolic deliv-
ery. Such can be achieved by optimization of liposomal
formulations of AAI to contain higher amounts of detergent.
Alternatively, more potent pH-sensitive detergents based on
stronger bases such as morpholine or piperazine can be
synthesized to mediate efficient cytosolic delivery of entrap-
ped macromolecules.
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